One medication's popularity dropped since a competitor works better, so there's incentive to push people back toward the first option. A newer compound is coming that outperforms the current leader, but since it's made by the same company, pricing will probably stay elevated to protect the existing product line. In a couple years once similarly effective alternatives from other companies show up, that's probably when pricing finally comes down.